NCCN Corporate Council

The NCCN Corporate Council is an important resource for the development and expansion of NCCN programs and resources. NCCN offers membership in the NCCN Corporate Council in order to significantly enhance collaborative efforts between pharmaceutical, biotechnical and diagnostic companies and NCCN and thus, better serve patients.

NCCN gratefully acknowledges the support and commitment of the following companies to the improvement of the treatments available to the patients whom we all serve. We also appreciate the recognition of NCCN's necessary autonomy in all decision-making regarding the conclusions, recommendations and outcomes of NCCN programs and resources.


NCCN Corporate Council Membership may include attendance at the semi-annual Corporate Council meetings, complimentary registration to NCCN educational programming, complimentary tuition to NCCN Academy for Excellence & Leadership in Oncology™, subscriptions to NCCN Flash Updates™, and receipt of the NCCN Corporate Council Newsletter. Membership also allows for regular communication with NCCN throughout the year. Memberships may be customized to include additional programming, such as support of and attendance to NCCN Policy Summits, exhibit space at NCCN conferences and meetings, licensing of and permission for NCCN Content, and NCCN Trends™ questions.

For additional information on the NCCN Corporate Council please contact Kieran Berkery, Business Development Specialist.


The next NCCN Corporate Council Meeting will take place as a live webinar on March 15, 2021. More information will be provided as it becomes available.

Global NCCN Corporate Council

NCCN is grateful for the support of our Global NCCN Corporate Council Members. To view a full list of NCCN Global Corporate Council Members, click here.

For additional information on the NCCN Global Corporate Council please contact Tracy McDowell, Manager, Global Business Development.

NCCN Corporate Council Members

  • abbvie-118x21
  • adaptive118x37
  • ADCT-118x68
  • Agios118x58
  • alkermes118x39
  • ambry118x33
  • AmerisourceBergen118
  • amgen118
  • apobiologix-118x26
  • astellas118
  • astraZen118
  • Athenex118x52
  • bayer118
  • BeiGene-118x40
  • Bluebird118x30
  • blueprintmedicines118x41
  • Boehringer118
  • bms118
  • clovis118
  • Coherus118x71
  • Castle118x35
  • daiichi-sankyo-118x36
  • DecipherBio118
  • dendreon118
  • eisai118
  • ElevarTherapeutics118x63
  • EMD118
  • Epizyme-118x46
  • ExactSciences118x59
  • exelixis118
  • eusapharma-118x25
  • fennec118x65
  • foundationMedicine118
  • Freenome118x39)
  • GITherapeutics118x88
  • galera-118x91
  • genettech118
  • Genmab118x35
  • GSK118
  • guardant118x25
  • herontherapeutics118
  • hologic118
  • idera118x55
  • incyte-118x85
  • Invitae118x34
  • ipsen-118
  • janssen118
  • jazz118
  • karyo118
  • KitePharma118x52
  • kyowa-kirin118
  • lexicon118x50
  • lilly118
  • mei118
  • merck118
  • morphosys118
  • myovant118
  • myriad118
  • novarts118
  • novocure118x33
  • oncopeptides-118x118
  • pfizer118
  • Paxman-118x38
  • pharmacyclics118
  • phrma118x51
  • pgnx_118x36
  • puma-118x40
  • QED118x73
  • regeneron118
  • sandoz118
  • sanofi-118
  • sdponcology118x34
  • Seagen118
  • Servier118x72
  • spectrum118
  • stemline118
  • sunpharma118
  • taiho118
  • takeda-118x59
  • TerSera118x41
  • tg-118x31
  • UroGen118x34
  • verastem-118x34
For additional opportunities to support NCCN, please visit the Supporter Opportunities section of our website.